Biomerica(BMRA) GlobeNewswire News Room·2025-02-19 13:19Core Insights - Biomerica, Inc. has announced that patients with Irritable Bowel Syndrome (IBS) can achieve significant relief from abdominal pain through a dietary therapy guided by the inFoods IBS blood test, as demonstrated in a clinical trial published in Gastroenterology [1][5]. Group 1: Product Overview - The inFoods IBS test identifies individual foods that trigger elevated Immunoglobulin G (IgG) antibody responses, which are markers of inflammation associated with IBS symptoms [2]. - The test is unique in its design, providing results with a 95% confidence interval cutoff, making it more reliable than previous IgG testing methods [2][6]. Group 2: Clinical Trial Findings - A randomized, multicenter, double-blind, placebo-controlled trial involved 238 IBS patients, showing that 59.6% of those in the treatment group met the FDA-standard target for abdominal pain reduction, compared to 42.2% in the control group [5]. - The benefits were particularly notable in patients with constipation-predominant IBS (IBS-C) and mixed IBS (IBS-M), with 67.1% and 66% of patients in the treatment group meeting the FDA target for pain reduction, respectively [5]. Group 3: Implications for IBS Management - The inFoods IBS test allows for a personalized dietary approach, enabling patients to eliminate only a few specific trigger foods rather than following restrictive diets like the low-FODMAP diet [10]. - This precision nutrition approach is significant, especially for IBS-M patients, as there are currently no FDA-approved medications for this subtype [12]. Group 4: Expert Commentary - Experts emphasize the importance of identifying dietary triggers for IBS patients, noting that the inFoods IBS test can help in this regard [11]. - The study's design addresses limitations of previous research, such as small sample sizes and inadequate IgG tests for IBS patients, paving the way for more effective dietary recommendations [7][8].